Harvard Bioscience (HBIO)

• Market cap: $22.5M
• 1 day: -2.79%
• 5 days: 22.43%
• 1 month: 37.29%
• 3 months: -20.51%
• 6 months: -76.44%
• Year to date: -74.94%
• 1 year: -82.52%
• 5 years: -81.29%
• 10 years: -90.31%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

Employees: 355

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more call options, than puts

Call options by funds: $5K | Put options by funds: $4K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

4% less funds holding

Funds holding: 95 [Q4 2024] → 91 (-4) [Q1 2025]

12.98% less ownership

Funds ownership: 71.17% [Q4 2024] → 58.18% (-12.98%) [Q1 2025]

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

41% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 37

78% less capital invested

Capital invested by funds: $65.5M [Q4 2024] → $14.5M (-$51M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 490% upside
• Avg. target: $3 490% upside
• High target: $3 490% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Benchmark Bruce Jackson

490% upside $3

Speculative Buy Maintained

13 May 2025